BioGenerator Ventures

IN10T Inc. is a digital agriculture company based in Chesterfield, Missouri, founded in 2016. The company specializes in designing and developing an internet-based platform for agronomic field research and data feeds. IN10T focuses on addressing farmer adoption challenges by providing customized digital and data science solutions tailored to the needs of agricultural stakeholders and investors. In addition to its platform, IN10T offers agricultural field data analysis and farm field testing services, enabling clients to make informed decisions based on comprehensive field data.

Solis Agrosciences is a plant science services company founded in 2021, dedicated to advancing research and development in crop innovation for Agtech firms. The company focuses on providing state-of-the-art technology and research services that facilitate the rapid testing and delivery of new plant traits. Its comprehensive end-to-end pipeline encompasses gene-editing and the generation and characterization of transgenic plants. By supporting emerging startups within the biotechnology ecosystem, Solis Agrosciences aims to enhance scientific discovery and commercialization in the agricultural sector, equipping its clients with the necessary tools and services to meet their research needs.

Peptyde Bio is an Agtech startup focused on combating fungal diseases through innovative bio-fungicidal technology. The company specializes in developing natural antimicrobial peptides (AMPs) sourced from plants, which offer a cost-effective and efficient alternative for treating such diseases. By leveraging these natural compounds, Peptyde Bio aims to establish itself as a leading supplier of AMPs, providing effective solutions for agricultural challenges while promoting sustainable practices in crop protection.

Geneoscopy, LLC is a diagnostics company based in Saint Louis, Missouri, that specializes in non-invasive colorectal cancer screening and gastrointestinal disease management. Founded in 2015, Geneoscopy has developed a platform technology that utilizes stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel. This innovative approach allows for the identification of colorectal cancer by capturing the downstream effects of cancer-causing DNA mutations. The company's diagnostic test aims to improve compliance with colorectal cancer screening, facilitate early-stage detection of neoplasms, and ultimately reduce morbidity and mortality associated with the disease. Additionally, Geneoscopy is exploring other applications of its technology for various gastrointestinal conditions, aiming to provide reliable alternatives to traditional invasive procedures like colonoscopy.

Buck Surgical is a medical device manufacturer specializing in surgical technologies that enhance patient outcomes and increase access to care. The company's patented coupling technology addresses anastomotic failures, offering a novel and efficient method for performing anastomoses in vascular and gastrointestinal surgery. By providing modern surgical solutions, Buck Surgical enables healthcare professionals to deliver high-quality care to a broader range of patients.

Impetus AG is engaged in the development of innovative insect control solutions that prioritize safety, effectiveness, and sustainability. The company specializes in creating bi-specific plant-based proteins designed to protect crops from harmful insects. Utilizing Bacillus thuringiensis technology, Impetus AG's products enhance crop yield by integrating antibodies within plant structures. This approach addresses the challenge of insect resistance that has emerged with existing commercial insect control products, offering farmers durable alternatives that support sustainable agriculture.

SentiAR, Inc. is a digital health company based in St. Louis, Missouri, focused on developing a 3D augmented reality holographic platform aimed at enhancing interventional medical procedures. Incorporated in 2017 and originating from Washington University, SentiAR's technology allows for real-time holographic visualization of a patient's anatomy and catheter positioning during procedures, utilizing data from various imaging modalities such as CT and MRI. This innovative platform is designed to create an interactive and controllable interface for clinicians, thereby improving the accuracy and safety of cardiac arrhythmia treatments. SentiAR's mission is to significantly enhance the experience for both patients and healthcare providers in catheter lab environments. The company is currently working towards obtaining FDA approval for its platform.

CuriMeta is a company specializing in advanced real-world health data within the life sciences sector. The firm focuses on augmenting, curating, and transforming data from collaborating healthcare systems into secure, de-identified, aggregated datasets. These datasets are designed to be compliantly exchanged with researchers to advance medical science and develop lifesaving treatments. CuriMeta operates under strict standards of transparency, integrity, and accountability, utilizing a joint governance committee to review all data exchange requests. The company adheres to stringent data security, patient privacy, and compliance standards as mandated by collaborating data contributors and regulatory authorities. By facilitating the efficient exchange of real-world health data with the research community, CuriMeta aims to provide researchers with crucial insights needed to address urgent scientific and clinical challenges, ultimately improving healthcare for all.

Omniose is an early-stage biotechnology company focused on the development of next-generation conjugate vaccines aimed at combating infectious diseases. The company specializes in pneumococcal conjugate vaccines that leverage proprietary in vivo conjugating technology, allowing for broader protection against various bacterial strains. By utilizing bioconjugation technology, Omniose's approach circumvents reliance on synthetic chemistry techniques, thereby enhancing the efficiency of vaccine development. This innovative platform supports the creation of polysaccharide-protein conjugate-based vaccines targeting multiple respiratory pathogens, including Streptococcus pneumoniae, ultimately enabling healthcare professionals to provide more effective treatment options for patients.

Cadre Bioscience, LLC, founded in 2019 and based in Saint Louis, Missouri, is engaged in the development of therapeutics aimed at addressing various human diseases. The company focuses on accelerating the progression of early-stage therapeutic assets through a structured approach that emphasizes de-risking and development processes. Cadre Bioscience seeks to raise capital and attract skilled management to support its initiatives, facilitating the commercialization of innovative therapies for market access and patient benefit.

Healthy Bytes, Inc. is a healthcare company that specializes in personalized nutritional counseling through its innovative platform. Founded in 2014 and headquartered in Saint Louis, Missouri, with an additional office in New York, Healthy Bytes connects registered dietitians with employers to provide nutritional support for employees dealing with health issues such as obesity, diabetes, high blood pressure, and cardiovascular diseases. The platform facilitates private consultations, allowing users to book appointments with registered dietitians online. By utilizing their existing medical benefits, employees can access nutritional counseling at no additional cost, empowering them to lead healthier lifestyles. The company's approach enables dietitians to gain insight into their clients' eating habits, fostering more effective and tailored guidance.

Plastomics Inc. is a biotechnology company that specializes in chloroplast genetic engineering to enhance crop performance and nutritional quality. Founded in 2016 and based in Saint Louis, Missouri, the company utilizes a proprietary technology platform to insert beneficial traits into the chloroplasts of plant cells. This innovative approach allows seed companies to develop advanced biotech crops with a diverse array of traits while addressing current industry challenges. Plastomics' technology not only eliminates cross-pollination but also facilitates unique maternal inheritance, significantly reducing breeding timelines and associated costs. By focusing on gene stacking and rapid breeding, Plastomics aims to improve yield production and contribute to the advancement of agricultural biotechnology.

Journeys Metabolic is a digital solution provider focused on improving metabolic care for conditions such as obesity and type 2 diabetes. The company offers a six-month program that allows patients to receive care at home, utilizing an interoperable platform that meets HITRUST standards. This physician-developed program emphasizes sustained behavior modification and employs AI-driven precision pathways, as well as computer vision technology for food education. Additionally, it incorporates proprietary biomarker assessments to evaluate fat oxidation levels. By optimizing shared savings in metabolic diseases and nutrition-related disorders, Journeys Metabolic aims to support health systems and accountable care organizations in transitioning to value-based care models, all while minimizing the burden on care teams.

Aggio is an information technology company based in Saint Louis, Missouri, with an additional location in Madison, New Jersey. Founded in 2016, Aggio specializes in developing cloud-based software solutions tailored for the agriculture industry. The company's platform focuses on marketing and sales enablement, offering data-driven insights to support decision-making processes. By harmonizing multiple data sources, Aggio provides a comprehensive view of the market, enabling businesses to engage with customers and channel partners both online and offline through desktop or mobile devices.

KaloCyte Inc., established in 2016 and based in Baltimore, Maryland, is a pre-clinical stage healthcare biotechnology company focused on developing innovative solutions for life-threatening blood loss scenarios. The company's flagship product, ErythroMer, is an artificial red blood cell substitute designed to be dried and bio-inspired, intended for use when stored red blood cells are unavailable or undesirable. This product aims to address critical gaps in trauma care services by providing a demonstrated proof of concept for treating hemorrhage situations effectively.

Omniose is an early-stage biotechnology company focused on the development of next-generation conjugate vaccines aimed at combating infectious diseases. The company specializes in pneumococcal conjugate vaccines that leverage proprietary in vivo conjugating technology, allowing for broader protection against various bacterial strains. By utilizing bioconjugation technology, Omniose's approach circumvents reliance on synthetic chemistry techniques, thereby enhancing the efficiency of vaccine development. This innovative platform supports the creation of polysaccharide-protein conjugate-based vaccines targeting multiple respiratory pathogens, including Streptococcus pneumoniae, ultimately enabling healthcare professionals to provide more effective treatment options for patients.

Arch Innotek, LLC is a biotechnology company based in St. Louis, Missouri, that specializes in engineering microorganisms to produce natural ingredients beneficial for human and animal health. Founded in 2013, the company focuses on developing high-value molecules for various industries, including food, feed, pharmaceuticals, and cosmetics. Arch Innotek employs innovative fermentation processes, utilizing yeast to create natural carotenoid antioxidants and other sustainable ingredients. The company also offers services such as high-performance liquid chromatography (HPLC) analysis, liquid chromatography-mass spectrometry (LC-MS) analysis, protein purification, and molecular cloning, supporting its mission to provide healthier and affordable natural alternatives for consumers.

Start Right Foods specializes in the production of convenient, protein-packed breakfast foods aimed at promoting a fit and active lifestyle. The company offers a variety of products, including waffles, pancakes, frozen meals, and waffle sliders, all designed to deliver a nutritious and satisfying breakfast experience. Their waffles are enriched with egg and dairy proteins, while also incorporating essential fiber, fruits, and vegetables. Committed to health-conscious consumers, Start Right Foods ensures that its offerings are gluten-free and free from added sugars, making it easier for individuals to enjoy a wholesome breakfast every morning.

Impetus AG is engaged in the development of innovative insect control solutions that prioritize safety, effectiveness, and sustainability. The company specializes in creating bi-specific plant-based proteins designed to protect crops from harmful insects. Utilizing Bacillus thuringiensis technology, Impetus AG's products enhance crop yield by integrating antibodies within plant structures. This approach addresses the challenge of insect resistance that has emerged with existing commercial insect control products, offering farmers durable alternatives that support sustainable agriculture.

BacterioScan, Inc. is a medical device company based in St. Louis, Missouri, focused on diagnosing and treating infectious diseases. The company has developed the 216Dx UTI System, which detects bacteria indicative of urinary tract infections (UTIs) in clinical urine samples and helps identify suitable antibiotic treatments. Additionally, BacterioScan offers the 216R Antibiotic Susceptibility Testing System, designed to detect bacterial infections, assess antibiotic resistance, and provide clinicians with tailored antimicrobial resistance profiles. Its precision bench-top systems facilitate rapid detection and real-time quantification of microbial growth, significantly enhancing laboratory efficiency compared to traditional plating methods. This innovative approach not only aids clinicians in personalizing patient care but also supports researchers in accelerating the development of new antibiotics. BacterioScan's technology aims to improve the quality of antibiotic therapy and mitigate the risks associated with antibiotic resistance.

Canopy Biosciences, founded in 2016 and headquartered in St. Louis, Missouri, is a biotechnology company specializing in research tools for genetic engineering, molecular biology, and personalized medicine. The company offers a comprehensive range of products and services designed to facilitate gene editing, gene expression analysis, and bioprocessing. One of its key technologies, TUNR, targets translation elongation by inserting polyA tracks into specific coding regions of the genome, effectively reducing mRNA levels and suppressing protein expression. This innovative approach supports biomedical researchers at universities, research institutions, and within the biotechnology and pharmaceutical sectors, accelerating scientific discovery and enhancing the field of genetic engineering. Canopy Biosciences operates as a subsidiary of Bruker Corporation.

Kypha Inc. is a life sciences company focused on the discovery, development, and commercialization of in-vitro diagnostic biomarker tests targeting inflammation and autoimmune disorders. Based in St. Louis, Missouri, the company offers the COMP ACT System, which enhances the monitoring and treatment of various health conditions, including lupus, stroke, traumatic brain injury, preeclampsia, infection, kidney disease, and transplant rejection. Through its innovative platform, Kypha provides rapid and accurate assessments of inflammation levels, enabling healthcare professionals to make timely and informed clinical decisions. The company's approach facilitates testing across diverse settings, from home health care to clinical laboratories, ultimately aiming to improve patient outcomes by optimizing treatment strategies based on real-time immune insights. Since its incorporation in 2009, Kypha has attracted significant funding and built a strong network of scientific and clinical expertise to support its mission.

Atomation is a company specializing in Internet of Things (IoT) solutions, providing software and hardware development kits to facilitate the creation of smart objects. Founded in 2014 and headquartered in St. Louis, Missouri, with additional locations in Tel Aviv, Israel, and Philadelphia, Pennsylvania, Atomation focuses on connecting existing, in-field legacy objects and assets to the internet. The company's platform serves sectors such as agriculture, medical, industrial, and logistics, enabling clients to gather data from various devices, including home automation systems, medical equipment, and industrial machinery. By transforming sensor data into actionable information, Atomation allows businesses to optimize operations and make informed real-time decisions, ultimately enhancing their efficiency and profitability.

Plastomics Inc. is a biotechnology company that specializes in chloroplast genetic engineering to enhance crop performance and nutritional quality. Founded in 2016 and based in Saint Louis, Missouri, the company utilizes a proprietary technology platform to insert beneficial traits into the chloroplasts of plant cells. This innovative approach allows seed companies to develop advanced biotech crops with a diverse array of traits while addressing current industry challenges. Plastomics' technology not only eliminates cross-pollination but also facilitates unique maternal inheritance, significantly reducing breeding timelines and associated costs. By focusing on gene stacking and rapid breeding, Plastomics aims to improve yield production and contribute to the advancement of agricultural biotechnology.

SentiAR, Inc. is a digital health company based in St. Louis, Missouri, focused on developing a 3D augmented reality holographic platform aimed at enhancing interventional medical procedures. Incorporated in 2017 and originating from Washington University, SentiAR's technology allows for real-time holographic visualization of a patient's anatomy and catheter positioning during procedures, utilizing data from various imaging modalities such as CT and MRI. This innovative platform is designed to create an interactive and controllable interface for clinicians, thereby improving the accuracy and safety of cardiac arrhythmia treatments. SentiAR's mission is to significantly enhance the experience for both patients and healthcare providers in catheter lab environments. The company is currently working towards obtaining FDA approval for its platform.

CoverCress Inc. is a biotechnology company based in Saint Louis, Missouri, founded in 2013. The company focuses on developing and commercializing field pennycress as an oilseed crop, which is utilized for producing oil for renewable fuels and meal for livestock feed. By genetically improving pennycress, CoverCress aims to create a sustainable cover crop that enhances soil health and offers benefits for farmers during corn and soybean planting seasons. The company’s efforts are centered on sustainable agricultural practices, allowing farmers to maximize yields while minimizing input and carbon emissions. Formerly known as Arvegenix Inc., CoverCress reflects a commitment to innovation in agriculture, biotechnology, and renewable energy solutions.

S4 is a technology service company that provides risk management solutions to ensure food production. It also develops index-based coverage to transfer the agriculture industry's volatilities to the financial markets, through OTC-derivatives contracts. The company offers products and services are used by a broad range of customers including large growers, crop protection and seeds suppliers, crop insurance providers, banking, and commodity exchanges. S4 integrates the harvest information with a planting plan, seed density, and soil analysis. They had developed a decision-making geo-referenced platform for the agricultural producer. They seek to improve the decision-making process in complex environments to collaborate in the global challenge of generating quality food for humanity. S4 was founded on 2011 and is headquartered in Buenos Aires, Argentina.

MedAware Solutions, Inc. is a healthcare technology company based in St. Louis, Missouri, founded in 2014. It specializes in providing a comprehensive platform that facilitates communication and coordination among healthcare teams, including providers, payers, patients, and their families. The company's flagship product, mViva, serves as an all-in-one care coordination tool that allows multi-disciplinary teams to engage with patients throughout the continuum of care. This secure, HIPAA-compliant platform enables users to capture and share data efficiently, fostering collaboration and enhancing patient outcomes. By empowering individuals to participate in real-time conversations and access connected care, MedAware Solutions aims to optimize clinical resources and reduce healthcare costs.

Accuronix Therapeutics, established in 2015 and headquartered in the United States, is a clinical-stage biopharmaceutical company focused on developing novel oncology therapies for pancreatic cancer. The company's proprietary technology enables selective targeting of Sigma-2 receptors overexpressed on cancer cells, aiming to reduce toxicity risk during treatment.

Edison Agrosciences, Inc. is an agricultural biotechnology company based in Durham, North Carolina, established in 2013. It specializes in developing innovative biotechnological solutions for the production of plant-based industrial materials, particularly focusing on alternative rubber crops. The company employs advanced computational breeding and agronomic techniques to enhance rubber concentration in underutilized plant parts, thereby improving per-acre yields. Edison Agrosciences aims to provide sustainable natural rubber sourced from alternative sunflower crops, catering to consumer, medical, and industrial markets. With a growing intellectual property portfolio and a commitment to forming strategic partnerships, the company seeks to mitigate risks associated with pilot-scale crop and product validation while driving advancements in sustainable biomaterials.

S4 is a technology service company that provides risk management solutions to ensure food production. It also develops index-based coverage to transfer the agriculture industry's volatilities to the financial markets, through OTC-derivatives contracts. The company offers products and services are used by a broad range of customers including large growers, crop protection and seeds suppliers, crop insurance providers, banking, and commodity exchanges. S4 integrates the harvest information with a planting plan, seed density, and soil analysis. They had developed a decision-making geo-referenced platform for the agricultural producer. They seek to improve the decision-making process in complex environments to collaborate in the global challenge of generating quality food for humanity. S4 was founded on 2011 and is headquartered in Buenos Aires, Argentina.

Nitrogenics is a plant biotechnology company providing research analysis on nitrogen fixation in crop plants. Nitrogenics' services include data related to plant enzymes that are inserted in the genome of tobacco, enabling researchers to get to research on plants that absorbs nitrogen directly from the atmosphere, rather than from fertilized soil.

Antegrin Therapeutics, LLC, is a drug discovery and development company focused on the development of novel therapies for fibrotic diseases. Our lead program aims to develop a treatment for idiopathic pulmonary fibrosis, a progressive, life-threatening condition that currently has no FDA-approved medication.

MedSocket is a company that specializes in clinical decision support systems aimed at enhancing the efficiency and quality of patient care. It offers two patented technologies: the 1-Click Decision Support (1-CDS) system and a medical search engine called 1-Search. Designed by clinicians for clinicians, these tools provide rapid access to evidence-based information at the point of care, addressing the urgent information needs of healthcare providers. Both technologies have been successfully piloted at the University of Missouri Health System, demonstrating their potential to improve healthcare decisions, reduce errors, and ultimately enhance patient outcomes. MedSocket was founded by Dr. Karl Kochendorfer, who recognized the challenges healthcare providers faced in accessing timely information, and was later joined by Matt Botkin and Jayne Williams to bring together expertise in business and information science. The company aims to alleviate the burden on clinicians by streamlining information retrieval and decision-making processes in healthcare settings.

Euclises Pharmaceuticals, Inc. is a biopharmaceutical company focused on researching, developing, and commercializing innovative medicines for inflammation and oncology. Founded in 2011 and headquartered in Saint Louis, Missouri, the company aims to create novel pain and cancer treatments that demonstrate superior safety profiles compared to existing medications. Euclises Pharmaceuticals leverages groundbreaking inventions from Dr. John Talley, a renowned medicinal chemist known for his development of several approved drugs, including Celebrex. The company's research is centered on compounds that promise enhanced efficacy and safety, positioning Euclises as a significant player in the pharmaceutical industry. It operates out of the BioGenerator Accelerator Labs, fostering a collaborative environment for its innovative pursuits.

Cofactor Genomics is a biotechnology company that specializes in predictive immune modeling and RNA sequencing. By advancing precision medicine, Cofactor aims to address existing barriers in the healthcare sector, transitioning from single-analyte biomarkers to comprehensive multidimensional biomarkers through health expression models. The company operates one of the first CAP-certified clinical RNA sequencing laboratories, which enhances the efficiency and cost-effectiveness of clinical trials for their partners. Cofactor’s expertise encompasses molecular biology, informatics, and database management, allowing them to provide high-quality services tailored to the needs of the healthcare and pharmaceutical industries. Their focus on RNA biomarkers associated with responses to targeted therapeutics supports the commercialization of clinical diagnostic assays for oncologic, immunologic, and neurodegenerative diseases, ultimately contributing to medical research and improved patient outcomes.

Confluence Life Sciences, Inc. is a drug discovery company based in Saint Louis, Missouri, specializing in the design and development of mechanistically novel kinase inhibitors for human and animal health care. Founded in 2010, the company utilizes its KINect technology platform to identify and develop new drugs targeting key enzymes involved in cancer growth, survival, and metastasis, as well as in chronic inflammatory diseases. Confluence Life Sciences distinguishes itself by focusing on novel binding sites and previously undrugged kinases, addressing challenges that other programs have overlooked. The company is supported by a team of experts with extensive pharmaceutical experience in kinase inhibitor discovery and development, enabling it to pursue innovative strategies and targets. Confluence Life Sciences aims to establish scientific and business collaborations to enhance its program pipeline, which follows a cycle of discovery, development, and partnership to meet unmet medical needs.

GeneriCo, LLC is a pharmaceutical company that specializes in the development and marketing of generic medications. Founded in 2013 and headquartered in Saint Louis, Missouri, with additional offices in Bengaluru, India; Italy; and South Korea, GeneriCo focuses on foundational medicines across various therapeutic areas, including cardiovascular health, pain management, central nervous system disorders, oncology, and aging-related conditions. The company distinguishes itself by targeting niche generic pharmaceuticals that have been overlooked by larger competitors, particularly those that involve complex formulations and innovative drug delivery technologies. This strategic focus allows GeneriCo to address specific market needs that are often neglected by mid-sized and large generic companies. GeneriCo serves a global customer base, providing essential medications that contribute to improved health outcomes.

NeuroLutions Inc., established in 2007 and headquartered in St. Louis, Missouri, specializes in developing non-invasive brain-computer interface (BCI) devices. These devices utilize electroencephalography (EEG) technology to interpret intended muscle movements from the brain, enabling stroke survivors to restore lost arm function and improve range of motion through muscle re-education. The company aims to revolutionize neurorehabilitation by providing a non-invasive alternative to traditional invasive BCI therapies.

SanusEO, LLC is a St. Louis-based company that specializes in developing a mobile patient engagement platform (PEP) designed to enhance communication and care between patients and healthcare providers. Founded in 2012, the platform employs data analytics to deliver daily alerts and real-time participant data to care teams, facilitating timely interventions for chronic disease management. SanusEO offers targeted programs such as transition care for patients recently discharged from hospitals and bootcamps for newly diagnosed or at-risk individuals. The platform promotes behavior modification in key health areas, including medication adherence, vital monitoring, diet, and physical activity, with capabilities for multi-language support. By streamlining engagement and intervention processes, SanusEO aims to improve patient outcomes while reducing healthcare costs.

CoverCress Inc. is a biotechnology company based in Saint Louis, Missouri, founded in 2013. The company focuses on developing and commercializing field pennycress as an oilseed crop, which is utilized for producing oil for renewable fuels and meal for livestock feed. By genetically improving pennycress, CoverCress aims to create a sustainable cover crop that enhances soil health and offers benefits for farmers during corn and soybean planting seasons. The company’s efforts are centered on sustainable agricultural practices, allowing farmers to maximize yields while minimizing input and carbon emissions. Formerly known as Arvegenix Inc., CoverCress reflects a commitment to innovation in agriculture, biotechnology, and renewable energy solutions.

Euclises Pharmaceuticals, Inc. is a biopharmaceutical company focused on researching, developing, and commercializing innovative medicines for inflammation and oncology. Founded in 2011 and headquartered in Saint Louis, Missouri, the company aims to create novel pain and cancer treatments that demonstrate superior safety profiles compared to existing medications. Euclises Pharmaceuticals leverages groundbreaking inventions from Dr. John Talley, a renowned medicinal chemist known for his development of several approved drugs, including Celebrex. The company's research is centered on compounds that promise enhanced efficacy and safety, positioning Euclises as a significant player in the pharmaceutical industry. It operates out of the BioGenerator Accelerator Labs, fostering a collaborative environment for its innovative pursuits.

Cardialen, Inc. is a medical device company based in Minneapolis, Minnesota, that specializes in developing innovative therapies for heart arrhythmias, particularly atrial fibrillation. Founded in 2008, the company focuses on creating implantable devices that provide low-energy, pain-free cardioversion therapies to restore normal heart rhythm. These devices utilize a proprietary technology that delivers a sequential series of low-voltage pulses to effectively address atrial fibrillation and other related conditions, such as rapid ventricular tachycardia and ventricular fibrillation, while minimizing patient discomfort and protecting heart tissue from damage. By targeting significant unmet medical needs, Cardialen aims to improve the quality of life for individuals suffering from these heart conditions.

RnAgri is a biotechnology company based in St Louis, Missouri, founded in 2011. The company specializes in developing innovative technology for producing ribonucleic acid (RNA). RnAgri's technology tackles challenges associated with mass-producing exogenous RNAi-based products through large-scale fermentation processes. This enables farmers to enhance and safeguard their crops and cattle by providing cost-efficient RNA production solutions.

SynerZ Medical, Inc. develops medical device for the treatment of obesity and type 2 diabetes. The company was incorporated in 2013 and is based in St. Louis, Missouri.

YourBevCo, LLC is a beverage device company focused on creating innovative consumer devices that address common concerns related to beverage ingredients. The company specializes in developing portable, recyclable, and single-use devices designed to remove problematic substances, such as sulfites in wine, which can trigger allergic reactions or sensitivities. By effectively eliminating these ingredients without altering the appearance, aroma, or taste of the beverages, YourBevCo enables consumers to enjoy their drinks safely and with peace of mind. The company's commitment to addressing health-related beverage issues positions it as a disruptive force in the consumer beverage market.

ImmunoPhotonics, Inc. is a biotechnology company focused on developing innovative immunotherapy-based treatments for cancer, specifically targeting metastatic solid tumors. Founded in 2008 and headquartered in Columbia, Missouri, the company has created a proprietary drug product that functions as a minimally invasive autologous cancer vaccine. This treatment involves the intratumoral injection of a carbohydrate polymer following tumor ablation, which harnesses the immune system's response to tumor-associated neoantigens released during the process. By doing so, ImmunoPhotonics aims to generate a systemic anti-tumor immune response, facilitating the treatment of late-stage metastatic cancers. The company has established a strategic partnership with Veterinary Cancer Therapeutics, LLC, enhancing its potential for clinical application.

Kypha Inc. is a life sciences company focused on the discovery, development, and commercialization of in-vitro diagnostic biomarker tests targeting inflammation and autoimmune disorders. Based in St. Louis, Missouri, the company offers the COMP ACT System, which enhances the monitoring and treatment of various health conditions, including lupus, stroke, traumatic brain injury, preeclampsia, infection, kidney disease, and transplant rejection. Through its innovative platform, Kypha provides rapid and accurate assessments of inflammation levels, enabling healthcare professionals to make timely and informed clinical decisions. The company's approach facilitates testing across diverse settings, from home health care to clinical laboratories, ultimately aiming to improve patient outcomes by optimizing treatment strategies based on real-time immune insights. Since its incorporation in 2009, Kypha has attracted significant funding and built a strong network of scientific and clinical expertise to support its mission.

Prostate Management Diagnostics creates tests and develops a fluid-based screening tool. It specializes in the fields of health diagnostics, medical, and healthcare. It was founded in 2014 and headquartered in San Francisco, California.

MedSocket is a company that specializes in clinical decision support systems aimed at enhancing the efficiency and quality of patient care. It offers two patented technologies: the 1-Click Decision Support (1-CDS) system and a medical search engine called 1-Search. Designed by clinicians for clinicians, these tools provide rapid access to evidence-based information at the point of care, addressing the urgent information needs of healthcare providers. Both technologies have been successfully piloted at the University of Missouri Health System, demonstrating their potential to improve healthcare decisions, reduce errors, and ultimately enhance patient outcomes. MedSocket was founded by Dr. Karl Kochendorfer, who recognized the challenges healthcare providers faced in accessing timely information, and was later joined by Matt Botkin and Jayne Williams to bring together expertise in business and information science. The company aims to alleviate the burden on clinicians by streamlining information retrieval and decision-making processes in healthcare settings.

Euclises Pharmaceuticals, Inc. is a biopharmaceutical company focused on researching, developing, and commercializing innovative medicines for inflammation and oncology. Founded in 2011 and headquartered in Saint Louis, Missouri, the company aims to create novel pain and cancer treatments that demonstrate superior safety profiles compared to existing medications. Euclises Pharmaceuticals leverages groundbreaking inventions from Dr. John Talley, a renowned medicinal chemist known for his development of several approved drugs, including Celebrex. The company's research is centered on compounds that promise enhanced efficacy and safety, positioning Euclises as a significant player in the pharmaceutical industry. It operates out of the BioGenerator Accelerator Labs, fostering a collaborative environment for its innovative pursuits.

ImmunoPhotonics, Inc. is a biotechnology company focused on developing innovative immunotherapy-based treatments for cancer, specifically targeting metastatic solid tumors. Founded in 2008 and headquartered in Columbia, Missouri, the company has created a proprietary drug product that functions as a minimally invasive autologous cancer vaccine. This treatment involves the intratumoral injection of a carbohydrate polymer following tumor ablation, which harnesses the immune system's response to tumor-associated neoantigens released during the process. By doing so, ImmunoPhotonics aims to generate a systemic anti-tumor immune response, facilitating the treatment of late-stage metastatic cancers. The company has established a strategic partnership with Veterinary Cancer Therapeutics, LLC, enhancing its potential for clinical application.

Confluence gathers, filters, combines and presents the pharmaceutical intelligence you need. It turns manual into automatic, risk into reliability and wait into wow. With Confluence you start where it counts: crucial planning and decision-making. Skip the assembly, start with Confluence.

Benson Hill is an agricultural technology company that specializes in crop improvement and soy protein innovation. The company focuses on unlocking the natural genetic diversity of plants to develop healthier, more sustainable food and ingredients. Its proprietary CropOS platform leverages machine learning and big data alongside traditional breeding techniques to streamline and expedite the product development process. Benson Hill operates a Crop Accelerator designed for rapid prototyping and is actively developing a seed portfolio that includes protein ingredients, aquaculture, specialty animal feed, and vegetable oils. The company generates revenue from both proprietary and non-proprietary product categories, with proprietary revenue stemming from the sale of its unique bean varieties.

Tansna Therapeutics, Inc. is a drug discovery and development company focused on creating innovative oral medications for the treatment of epilepsy and other central nervous system disorders. Established in 2010 and headquartered in St. Louis, Missouri, the company is dedicated to developing novel therapies aimed at improving the lives of patients suffering from debilitating conditions. Its main product in development is an oral anticonvulsant agent designed to effectively reduce seizure frequency in individuals with epilepsy, providing healthcare professionals with enhanced treatment options for their patients.

BacterioScan, Inc. is a medical device company based in St. Louis, Missouri, focused on diagnosing and treating infectious diseases. The company has developed the 216Dx UTI System, which detects bacteria indicative of urinary tract infections (UTIs) in clinical urine samples and helps identify suitable antibiotic treatments. Additionally, BacterioScan offers the 216R Antibiotic Susceptibility Testing System, designed to detect bacterial infections, assess antibiotic resistance, and provide clinicians with tailored antimicrobial resistance profiles. Its precision bench-top systems facilitate rapid detection and real-time quantification of microbial growth, significantly enhancing laboratory efficiency compared to traditional plating methods. This innovative approach not only aids clinicians in personalizing patient care but also supports researchers in accelerating the development of new antibiotics. BacterioScan's technology aims to improve the quality of antibiotic therapy and mitigate the risks associated with antibiotic resistance.

GeneriCo, LLC is a pharmaceutical company that specializes in the development and marketing of generic medications. Founded in 2013 and headquartered in Saint Louis, Missouri, with additional offices in Bengaluru, India; Italy; and South Korea, GeneriCo focuses on foundational medicines across various therapeutic areas, including cardiovascular health, pain management, central nervous system disorders, oncology, and aging-related conditions. The company distinguishes itself by targeting niche generic pharmaceuticals that have been overlooked by larger competitors, particularly those that involve complex formulations and innovative drug delivery technologies. This strategic focus allows GeneriCo to address specific market needs that are often neglected by mid-sized and large generic companies. GeneriCo serves a global customer base, providing essential medications that contribute to improved health outcomes.

Adarza BioSystems is an early-stage medical diagnostics company based in St. Louis, Missouri, that specializes in developing a rapid and label-free biological assay platform for clinical and point-of-care samples. Founded in 2008, the company utilizes its innovative arrayed imaging reflectometry technology to enable the simultaneous detection of hundreds of analytes from a single drop of fluid. This platform allows healthcare professionals to conduct sophisticated tests in a matter of minutes, ensuring high sensitivity and specificity in the detection of multiplexed proteins. Adarza BioSystems aims to enhance diagnostic capabilities, improving patient outcomes through quicker and more accurate testing.

Antegrin Therapeutics, LLC, is a drug discovery and development company focused on the development of novel therapies for fibrotic diseases. Our lead program aims to develop a treatment for idiopathic pulmonary fibrosis, a progressive, life-threatening condition that currently has no FDA-approved medication.

Indalo Therapeutics is a preclinical-stage biotechnology company focused on developing innovative therapies for patients affected by fibrotic diseases. The company is built on significant scientific advancements and aims to address critical unmet medical needs in the fibrosis domain. By leveraging advanced understanding of the molecular mechanisms behind abnormal scarring, Indalo Therapeutics seeks to create treatments that can halt or even reverse fibrosis. The organization is comprised of a skilled team of pharmaceutical scientists and executives, dedicated to improving patient outcomes through novel therapeutic approaches.

MediBeacon Inc. is a medical technology company specializing in real-time kidney function monitoring solutions. Founded in 2012 and based in St. Louis, Missouri, the company develops innovative optical diagnostic systems aimed at enhancing patient care. Its flagship product, the NIC-Kidney device, allows for the monitoring of glomerular filtration rate (mGFR) in preclinical settings. MediBeacon also offers a renal function system that combines an optical skin sensor with a proprietary fluorescent agent, enabling continuous real-time monitoring of kidney function. This technology is particularly beneficial in intensive care units and operating rooms, where it helps clinicians optimize patient outcomes and dosing strategies. The company has a robust intellectual property portfolio that includes additional product concepts for physiological monitoring and imaging of pathological diseases, positioning it as a leader in nephrology and optical diagnostics.

Tansna Therapeutics, Inc. is a drug discovery and development company focused on creating innovative oral medications for the treatment of epilepsy and other central nervous system disorders. Established in 2010 and headquartered in St. Louis, Missouri, the company is dedicated to developing novel therapies aimed at improving the lives of patients suffering from debilitating conditions. Its main product in development is an oral anticonvulsant agent designed to effectively reduce seizure frequency in individuals with epilepsy, providing healthcare professionals with enhanced treatment options for their patients.

Benson Hill is an agricultural technology company that specializes in crop improvement and soy protein innovation. The company focuses on unlocking the natural genetic diversity of plants to develop healthier, more sustainable food and ingredients. Its proprietary CropOS platform leverages machine learning and big data alongside traditional breeding techniques to streamline and expedite the product development process. Benson Hill operates a Crop Accelerator designed for rapid prototyping and is actively developing a seed portfolio that includes protein ingredients, aquaculture, specialty animal feed, and vegetable oils. The company generates revenue from both proprietary and non-proprietary product categories, with proprietary revenue stemming from the sale of its unique bean varieties.

Confluence Life Sciences, Inc. is a drug discovery company based in Saint Louis, Missouri, specializing in the design and development of mechanistically novel kinase inhibitors for human and animal health care. Founded in 2010, the company utilizes its KINect technology platform to identify and develop new drugs targeting key enzymes involved in cancer growth, survival, and metastasis, as well as in chronic inflammatory diseases. Confluence Life Sciences distinguishes itself by focusing on novel binding sites and previously undrugged kinases, addressing challenges that other programs have overlooked. The company is supported by a team of experts with extensive pharmaceutical experience in kinase inhibitor discovery and development, enabling it to pursue innovative strategies and targets. Confluence Life Sciences aims to establish scientific and business collaborations to enhance its program pipeline, which follows a cycle of discovery, development, and partnership to meet unmet medical needs.

Euphrates Vascular is a medical technology company based in St. Louis, Missouri, that focuses on innovative solutions for the treatment of stroke, heart disease, and other conditions. The company has developed a proprietary magnetically-enhanced diffusion (MED) system that utilizes magnet-based technology to dissolve blood clots more rapidly than existing treatment options. This system aims to improve the efficacy of FDA-approved clot-busting medications, potentially reducing mortality rates associated with stroke and cardiovascular diseases. In addition to the MED system, Euphrates Vascular offers MED MicroBeads, which are designed to deliver therapeutic agents directly to clots during thrombolysis therapy, and a touch screen-operated MED Workstation. Founded by physicists with extensive experience in medical technology, the company continues to advance its pioneering approaches in the healthcare sector, attracting interest from investors and media alike.

Apertus Pharmaceuticals is a manufacturer of Active Pharmaceutical Ingredients (APIs) serving dosage form manufacturing companies in the pharmaceutical industry. The company supplies both controlled and non-controlled substance APIs, as well as intellectual property, to its clients. Apertus Pharmaceuticals is committed to adhering to the principles of Green Chemistry as outlined by the FDA and aims to achieve higher purity standards than those currently mandated. The company is led by CEO Rick Ryan, Ph.D., and CSO David Gindelberger, Ph.D.

Kypha Inc. is a life sciences company focused on the discovery, development, and commercialization of in-vitro diagnostic biomarker tests targeting inflammation and autoimmune disorders. Based in St. Louis, Missouri, the company offers the COMP ACT System, which enhances the monitoring and treatment of various health conditions, including lupus, stroke, traumatic brain injury, preeclampsia, infection, kidney disease, and transplant rejection. Through its innovative platform, Kypha provides rapid and accurate assessments of inflammation levels, enabling healthcare professionals to make timely and informed clinical decisions. The company's approach facilitates testing across diverse settings, from home health care to clinical laboratories, ultimately aiming to improve patient outcomes by optimizing treatment strategies based on real-time immune insights. Since its incorporation in 2009, Kypha has attracted significant funding and built a strong network of scientific and clinical expertise to support its mission.

Companion Pharma is an animal health product development company that will develop innovative new formulations of drugs for use under prescription in companion animals. Companion will specifically target companion animal disease indications that have a high unmet treatment need and will provide 'pet friendly' drugs that are proven to work safely in the target species, are formulated in a way to provide ease of administration and are available in doses that meet the needs of the highly variable weight profile of companion animal pets.

Array Bridge specializes in providing high-quality products and services tailored for the pharmaceutical and biotechnology sectors. The company offers a range of products, including antibody arrays designed for biosimilar and antibody-drug conjugate three-dimensional conformational comparability analysis, as well as ELISA kits for detecting Host Cell Proteins from sources such as CHO and E. coli-derived biologics. Additionally, Array Bridge provides various services, including antibody production, method qualification and validation for binding-based bioassays, and analytical techniques like 1-D and 2-D gel analysis and Western Blot analysis for process-related impurities. The company’s focus on drug development also encompasses the detection of host cell protein and DNA contaminants, enabling clients to enhance their immunoassays and bio-therapeutic drug offerings.

RnAgri is a biotechnology company based in St Louis, Missouri, founded in 2011. The company specializes in developing innovative technology for producing ribonucleic acid (RNA). RnAgri's technology tackles challenges associated with mass-producing exogenous RNAi-based products through large-scale fermentation processes. This enables farmers to enhance and safeguard their crops and cattle by providing cost-efficient RNA production solutions.

ARTA Bioscience, Inc is developing new therapeutics for prostate cancer and inflammatory diseases. Current treatments for prostate cancer are insufficient and the disease is the second leading cause of cancer deaths among American men. ARTA's technology involves an entirely different approach to combating disease compared to traditional treatments. In addition to prostate cancer, the company's technologies may be used to target other important proteins in the nuclear receptor class. The company has established operations at the BioGenerator Accelerator Labs. ARTA's technology was developed by Dr. Marc Diamond at Washington University.

Mobius Therapeutics, LLC is a St. Louis-based company that specializes in developing sterile injectable pharmaceutical products for ophthalmic applications. Founded in 2006, the company focuses on creating innovative solutions for ophthalmic surgery. Its flagship product, Mitosol, is a kit designed for the safe delivery of mitomycin, an antifibrotic agent used in glaucoma, refractive, and corneal surgeries. This product includes a closed-system transfer device and sponge tray to facilitate the reconstitution and transfer of the drug. In addition to Mitosol, Mobius Therapeutics offers Amphadase, a hyaluronidase injection. The company primarily serves ophthalmologists and their patients, making its products available for online purchase. Currently, Mobius Therapeutics is in the process of seeking regulatory approval for its offerings, while continuing to explore additional product applications.

Array Bridge specializes in providing high-quality products and services tailored for the pharmaceutical and biotechnology sectors. The company offers a range of products, including antibody arrays designed for biosimilar and antibody-drug conjugate three-dimensional conformational comparability analysis, as well as ELISA kits for detecting Host Cell Proteins from sources such as CHO and E. coli-derived biologics. Additionally, Array Bridge provides various services, including antibody production, method qualification and validation for binding-based bioassays, and analytical techniques like 1-D and 2-D gel analysis and Western Blot analysis for process-related impurities. The company’s focus on drug development also encompasses the detection of host cell protein and DNA contaminants, enabling clients to enhance their immunoassays and bio-therapeutic drug offerings.

Confluence Discovery Technologies is a contract research organization specializing in drug discovery, particularly in the development of kinase inhibitors for cancer and inflammatory diseases. The company offers a range of technical services, including mechanistic enzymology, target validation and characterization, screening and assay development, as well as biomarker development and measurement. With a team of founders who were prominent scientific leaders in Pfizer's Inflammation Research Unit, Confluence brings decades of experience in developing clinical candidates targeting key enzymes that regulate cancer growth, survival, and metastasis, as well as those involved in chronic inflammation. The organization is based at the BioGenerator Accelerator Labs, positioning it within a collaborative environment for innovation in healthcare.

Euphrates Vascular is a medical technology company based in St. Louis, Missouri, that focuses on innovative solutions for the treatment of stroke, heart disease, and other conditions. The company has developed a proprietary magnetically-enhanced diffusion (MED) system that utilizes magnet-based technology to dissolve blood clots more rapidly than existing treatment options. This system aims to improve the efficacy of FDA-approved clot-busting medications, potentially reducing mortality rates associated with stroke and cardiovascular diseases. In addition to the MED system, Euphrates Vascular offers MED MicroBeads, which are designed to deliver therapeutic agents directly to clots during thrombolysis therapy, and a touch screen-operated MED Workstation. Founded by physicists with extensive experience in medical technology, the company continues to advance its pioneering approaches in the healthcare sector, attracting interest from investors and media alike.

PixelEXX Systems Inc. is a company based in Saint Louis, Missouri, that specializes in developing innovative imaging devices aimed at cancer diagnosis. Founded in 2008, the company focuses on creating prototype imaging technologies that utilize advanced nanoarrays to capture images of molecular signals linked to cellular activity. Their proprietary image sensors incorporate novel nano resonant photodiodes, which enhance sensitivity and allow for the capture of wavelength and polarization information without relying on microlenses, filters, or separate metasurfaces. This unique approach enables clients to optimize imaging and sensing capabilities while reducing size, weight, and power consumption of the devices.

APT Therapeutics, situated at 4041 Forest Park Ave., St. Louis, MO, specializes in biotechnology. The company focuses on developing an antiplatelet therapy derived from human apyrase, aiming to minimize damage during acute myocardial infarction and stroke events. Utilizing protein engineering, informatics, and cheminformatics software, APT Therapeutics creates innovative therapeutics to improve patient outcomes in cardiovascular emergencies and transplantation complications.